바이오다인

314930KOSDAQ의료용 기기 제조업

41.9 / 100

Reference Date: 2026-07-24

Financial Score11.0 / 40

News Sentiment16.9 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: PER raises overvaluation concerns, PBR raises overvaluation concerns. Declined 7.2% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

BioDain develops, manufactures, and sells liquid-based cytology (LBC) equipment and cancer diagnostic kits, leveraging its proprietary Blowing Technology to enhance diagnostic accuracy and usability. The company exports its products to 13 countries, including Japan, the U.S., and Europe, and collaborates with Roche to develop the VENTANA SP400 device, expanding its global market presence.

Number of Employees

23people

Average Salary

39.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

291.03Industry Average 20.040.0Point

14.5x industry avg (risky)

PBR

5.70Industry Average 1.140.0Point

5.0x industry avg (risky)

ROE

1.95Industry Average 8.001.0Point

Well below industry avg

Debt Ratio

—Industry Average 11.654.0Point

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲31.1% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲76.7% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -0.1% (improving, 3yr)

Detailed News Sentiment

2 totalPositive 1Neutral 1Negative 0Average Sentiment Score 67.5

Neutral
티그리스인베스트먼트 신임 대표이사에 정영고 전 동국인베스트먼트...
티그리스인베스트먼트의 대표이사 변경 소식은 바이오다인 주식에 직접적인 영향을 미치지 않는 일반 인사 이동 사항입니다.
Positive
바이오다인 ‘얼리팝’, EU MDR 적합성 평가 통과…러·베트남 출고 ...
바이오다인의 얼리팝 제품이 유럽 MDR 적합성 평가를 통과하여 해외 시장 진출에 긍정적 영향을 미칠 것으로 예상됩니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (5%, downtrend)

Current 8,440Won52-week high 16,31052-week low 8,000

1-month return1.0Point

1m -7.25% (falling)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-13
Neutral주식등의대량보유상황보고서(일반)2026-07-06
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-06